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CLINICAL INVESTIGATION
Contrast nephropathy in patients with impaired renal function:
High versus low osmolar media
BRENDAN J. BARRETT, PATRICK S. PARFREY, HILARY M. VAVASOUR, JACKIE MCDONALD,
GLORIA KENT, DONNA HEFFERTON, FRANK O'DEA, ERIC STONE, RM REDDY,
and PATRICK J. MCMANAMON
Divisions of Nephrology and Cardiology, Departments of Medicine and Radiology, The General Hospital, The Health Sciences Centre,
Memorial University, St. John's, Newfoundland, Canada
Contrast nephropathy in patients with impaired renal function: High
versus low osmolar media. Prescription of low osmolar contrast to
prevent nephrotoxicity in subjects with pre-existing renal impairment is
costly and has not been clearly shown to be effective. We entered 249
subjects with a pre-contrast serum creatinine greater than 120 mol/liter
(1.35 mg/dl) having cardiac catheterization or intravenous contrast into
a randomized controlled trial comparing high and low osmolar contrast.
The outcome assessed was a rise in serum creatinine repeated 48 to 72
hours after contrast. A further 117 patients entered the non-randomized
prospective arm of the study. In the randomized study the serum
creatinine rose by at least 25% after contrast in 8 of 117 (6.8%) given
high and in 5 of 132 (3.8%) given low osmolar contrast (P > 0.05,
one-tailed 95% confidence interval for the difference 3 to 7.8%). More
severe renal failure (greater than 50% increase in serum creatinine) after
contrast was uncommon (3.4% with high and 1.5% with low osmolar
contrast). A rise in serum creatinine after contrast was significantly
associated with the severity of the pre-contrast renal impairment and
the presence of diabetes mellitus, but not with type of contrast.
Diabetics with a serum creatinine greater than 200 smol/liter (2.25
mgldl) pre-contrast had a highest risk of deterioration in renal function
after contrast. We conclude that in patients with pre-existing renal
impairment the incidence of contrast nephropathy was not significantly
different comparing high osmolar and nonionic contrast. The potential
benefit of nonionic contrast in moderate renal impairment is likely to be
small, but trials in diabetics with severe renal impairment should be
undertaken urgently.
Contrast nephropathy may be defined as an acute toxic
nephropathy due to radiographic contrast media. There has
been considerable confusion in the literature about the inci-
dence of the condition [1]. We have previously shown that it is
not common with normal pre-existing renal function, but that it
is more frequent in patients with renal impairment, especially
when due to diabetic nephropathy [2, 31.
There has been difficulty in establishing an animal model of
contrast nephropathy [4]. This has hindered efforts to investi-
gate its pathogenesis and has led some to question the existence
of the condition [5]. Nevertheless, contrast has been shown to
have toxic effects in rabbits whose kidneys have been subjected
to other stresses [6].
It was expected that nonionic low-osmolar contrast would be
less nephrotoxic than ionic high-osmolar media. Some [7—91,
but not all studies [10, 11] of contrast-induced enzymuria and
proteinuria have suggested that low-osmolar media may be less
nephrotoxic. A randomized trial in humans, mostly with normal
renal function, did not find that low-osmolar media were less
nephrotoxic [121. In a noncomparative study, low-osmolar
contrast was associated with a 50% incidence of a 25% rise in
serum creatinine after cardiac catheterization in patients with
advanced diabetic nephropathy [13]. A randomized trial in
patients with pre-existing renal impairment undergoing cardiac
angiography found a statistically significantly smaller rise in
serum creatinine at 24 hours after nonionic contrast than after
ionic contiast [141. The authors of the study concluded that
nonionic contrast was less nephrotoxic than ionic, although
there was not a significant reduction in the incidence of clini-
cally important episodes of nephrotoxicity and no benefit was
seen in insulin requiring diabetics [14]. A recent randomized
trial of intravenous contrast in 101 patients with renal insuffi-
ciency suggested that high osmolar media were more likely than
nonionic agents to cause mild exacerbation of renal insuffi-
ciency [15]. However, there were few cases of clinically impor-
tant contrast nephropathy.
Because low-osmolar contrast is 10 to 20 times more expen-
sive than high-osmolar contrast we compared several adverse
reactions to these two agents in a randomized controlled trial of
3603 patients given intra-arterial or intravenous contrast, iden-
tified from a population of 5023 patients [16, 17]. Because
patients with impaired renal function have an increased risk of
contrast nephropathy [1—3], this cohort (N = 573)was identified
and follow-up serum creatinine levels were ordered to deter-
mine the relative nephrotoxicity of the two classes of contrast
media.
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Research design and study population
This study was one component of a large randomized trial
comparing ionic high-osmolar to nonionic low-osmolar contrast
in a population of 5023 patients, using a variety of outcomes
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Table 1. Source of patients with pre-existing renal impairment who underwent cardiac angiography or had a procedure requiring intravenous
contrast and entered the contrast nephropathy study
Randomized Non-randomized
Cardiac i.v. Total Cardiac i.v. Total
Serum creatinine measureda 1490 2113 3603 366 1054 1420
Serum creatinine > 120 mol/liter 153 222 375 57 105 162
Serum creatinine repeated after contrast 123
(80%)
126
(57%)
249
(66%)
50
(88%)
67
(64%)
117
(72%)
a All 5023 patients who entered the studies comparing high osmolar and nonionic contrast had serum creatinine measured. Only those with
elevated serum creatinine entered the contrast nephropathy limb.
including systemic reactions, hemodynamic adverse events and
severe symptoms [16, 17]. The trial was performed over the
three years prior to February 1991 at a university based tertiary
referral center. Patients having cardiac catheterization, intrave-
nous pyelography, or CT scanning with contrast were eligible.
All 5023 subjects entered in the study had their serum creatinine
measured within 24 hours prior to contrast administration.
Because the incidence of contrast nephropathy is very low in
patients with normal renal function [1] only subjects whose
serum creatinine exceeded 120 Lmol/liter (1.35 mg/dI) had
another measurement of serum creatinine ordered 48 to 72
hours after contrast. The population from which the study
group was identified, and the proportion of the group who had
follow-up serum levels measured is shown in Table 1.
The study population were stratified into those having cardiac
angiography (N = 1856) and those having intravenous contrast
(N 3167) before randomization, No attempt was made to
stratify for other factors related to nephrotoxicity because the
pre-contrast serum creatinine levels were frequently not avail-
able until after the imaging procedure was completed.
Some subjects were excluded from the randomized trials [16,
171. In the intravenous arm 1054 of 3167 patients were excluded
because of prior severe reaction to contrast, active asthma,
unavailability of low-osmolar contrast in a form suitable for the
patient's investigation, and patient or physician refusal to enter
the study. In the cardiac catheterization arm 366 of 1856
patients were excluded because of unstable angina, severe heart
failure, or any of the above. No subject was excluded because
of a perceived risk of nephrotoxicity. To allow recognition of
bias we followed all subjects irrespective of randomization
status. Table 1 shows the number of subjects who had a raised
serum creatinine along with the number of subjects who had a
second measurement of serum creatinine after contrast in the
various groups.
Many subjects were outpatients and were not seen by a
nephrologist prior to contrast. No routine prophylactic mea-
sures to prevent nephrotoxicity were employed before or after
imaging. Before randomization, details of demographic, clinical
(including any renal or cardiac disease and diabetes mellitus),
and medication history were recorded by the research nurse,
Subjects who had a 50% or greater rise in serum creatinine were
seen by a nephrologist after imaging. The medical records of all
subjects with at least a 25% increase in serum creatinine were
reviewed by a nephrologist, blind to the contrast administered,
to determine whether contrast was likely to have caused the
increase.
Outcomes
Serum creatinine was measured by autoanalyzer in several
different laboratories, as outpatient subjects attended their local
hospitals for follow-up. We defined a case of contrast nephrop-
athy as the unexplained occurrence of a 25% or greater incre-
ment in serum creatinine at 48 hours after contrast. We also
report more severe degrees of deterioration in renal function.
To facilitate comparison with other studies [12, 14], we report
the number who had a rise of at least 44 mol/liter (0.5 mg/dl) in
serum creatinine, and the mean change in serum creatinine after
each type of contrast.
Statistics and sample size
Incidence rates, means and standard deviations, medians and
ranges are used as appropriate to describe the data. The
frequency of events in the groups receiving high- and low-
osmolar contrast was compared by chi-squared tests or Fisher's
exact tests for 2 by 2 tables. Means were compared by t-tests
for unpaired data, while medians were compared by Mann-
Whitney U tests. We used a one-tailed a of 0.05 to declare
significance and we report one-tailed 95% confidence intervals
for differences between the randomized groups. We used mul-
tiple logistic (BMDP LR program, 1988) and multiple linear
regression (SPSS-X, 1988) models to examine, and adjust for,
the effect of covarjates on the outcomes. Cross overs were
handled by intention-to-treat analysis, but only one randomized
subject received both types of contrast and had a subsequent
rise in serum creatinine.
Before the study we estimated that the incidence of a 25%
rise in serum creatinine after high-osmolar contrast would be
10% [2]. To detect a 50% reduction in this incidence with
low-osmolar contrast, with a one-tailed a of 0.05 and a 3 of 0.2,
we required to randomly assign 332 subjects to each type of
contrast. However, enrollment in the contrast nephropathy
study was stopped when the objectives of the two associated
trials were achieved [16, 17]. Although the size of the sample
that could be analyzed was less than anticipated, we felt that the
data collected on these 366 subjects with renal impairment
should be reported now, because the patient number studied is
high in comparison to other studies, the incidence rates are
lower than expected, the current literature is not definitive, and
the subject is of clinical importance.
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Table 2. Baseline comparison of the patients in the randomized triala
High-osmolar
N=117 %
Low-osmolar
N=132 %
Total
Male 99 86.6 92 69.7
Diabetes mellitus 12 10.3 24 18.2
Serum creatinine 17 14.5 18 13.6
> 200 mol/liter
History of cardiac failure 18 15,4 20 15.2
Hypertensive 61 52.1 77 58.3
Bed bound in hospital 11 9.4 14 10.6
ACE inhibitor 13 11.1 15 11.4
Calcium channel blocker 49 41.9 48 36.4
Nonsteroidal 15 12.8 15 11.4
anti-inflammatory
Diuretic 30 25,6 31 23.5
Type of investigation
Cardiac catheterization 64 54.7 59 44.7
Intravenous pyelogram 19 16.2 34 25.8
Computed tomography 34 29.1 39 29.5
Mean SD Mean SD
Age years 64.3 10,7 64.0 12.3
Systolic blood pressure 140.6 26.5 142,8 23.6
mm Hg
Diastolic blood pressure 75.9 12.1 78.2 13.0
mm Hg
Weight kg 77.9 12.6 75.1 12.5
High-osmolar Low-osmolar
Median Range Median Range
Serum creatinine p.mollliter 138 120—685 138 120—572
Blood urea mmol/!iter 9.8 4—47 9.9 4.7—44
Contrast volume ml 120 50—400 100 40—400
8 All these patients had pre-contrast serum creatinine > 120 mol/
liter (1.35 mg/dl) and had follow-up serum creatinine performed 48 to 72
hours after contrast.
Results
Baseline comparison
Table 2 shows the baseline characteristics of the randomized
subjects who had a measurement of serum creatinine after
contrast. By chance more diabetics were given low-osmolar
contrast, while cardiac angiography was the investigation per-
formed in a greater proportion of those given high-osmolar
contrast.
Table 3 shows the same profile of baseline characteristics for
the subjects who were not entered in the randomized trial, but
who did have a second determination of serum creatinine. In
the early part of our study infusable low-osinolar contrast was
not available for CT of the body [16]. These patients were more
likely to have diseases associated with renal impairment. The
profile of the subjects who had low-osmolar contrast reflects the
fact that a majority had severe cardiac disease and had cardiac
angiography. Therefore it is not surprising that both groups had
higher serum creatinine levels than the corresponding random-
ized groups.
We examined the characteristics of those subjects who failed
to have a second serum creatinine determination. In the ran-
domized study these subjects differed from those having follow
Table 3. Baseline characteristics of the patients who did not enter
the randomized trial but whose renal function was prospectively
followed after contrast
High-osmolar
N=43 %
Low-osmolar
N=74 %
Total
Male 36 83.7 47 63.5
Diabetes mellitus 4 9.3 Il 14.9
Serum creatinine > 200 13 30.2 15 20.2
smol/liter
History of cardiac failure 8 18.6 25 33.8
Hypertensive 20 46.5 51 68.9
Bed bound in hospital 5 11.6 22 29.7
ACE inhibitor 3 7.0 12 16.2
Calcium channel blocker 5 11.6 32 43.2
Nonsteroidal 9 20.9 10 13.5
anti-inflammatory
Diuretic 13 30.2 29 39.2
Type of investigation
Cardiac catheterization 1 2.3 49 66.2
Intravenous pyelogram 2 4.6 9 12.2
Computed tomography 40 93.1 16 21.6
Mean SD Mean s
Age years 66.4 11.4 67.0 11.8
Systolic blood pressure 136.0 20.1 142.0 29.5
mm Hg
Diastolic blood pressure 79.0 11.7 75.0 15.3
mm Hg
High-osmolar Low-osmolar
Median Range Median Rangr
Serum creatinine p,moi/liter 159 120—502 141 120—65
Blood urea mmol/liter 11.8 6—32 10.3 5—66
Contrast volume ml 300 50—400 122.5 45—40
up in that a greater proportion had intravenous contra
(76.2%), and were outpatients, while a lesser proportion (7.191
had a serum creatinine greater than 200 prnol/liter (2.25 mgId1
Outcome of the trial
The difference between the two randomized groups, in term
of any of the outcome events, failed to reach statistical signil
icance (Table 4). Although the incidence of minor changes i
renal function after contrast was greater in the subjects wh
were not randomized, more severe acute renal failure was nc
significantly more common in these subjects (Table 4).
Following review of the records, it was felt that contrast wa
unlikely to have been responsible for the 25% rise in serur
creatinine after contrast in one subject randomized to higi
osmolar contrast, in two subjects nonrandomly receiving higF
osmolar contrast, and in one subject nonrandomly given loss
osmolar contrast. When these cases were excluded, th
incidence of a 25% increment in creatinine was 6% (95% CI 2.
to 11.9) in those randomized to high-osmolar, and 3.8% (95% C
1.2 to 8.6) in those randomized to low-osmolar contrast. Th
corresponding figures for the non-randomized groups wer
18.6% (95% CI 8.4 to 33.4) with high-osmolar and 9.5% (95% C
3.9 to 18.5) with low-osmolar contrast.
The mean change in serum creatinine by 48 to 72 hours afte
contrast was 3.5 tmol/liter (0.04 mg/dl) in those randomized t
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Table 4. The incidence of outcome events in the trial before removal
of cases where contrast was not felt to be the cause of the acute
renal failure
95% CI
for the
reduction
.
High-osmolar Low-osmolar
with low-
osmolar
N=117 % N=132 % %
Randomized subjects
Scr rise of 25% 8 6.8 5 3.8 3.0 to 7.8
Scr rise of 50% 4 3.4 2 1.5 1.9 to 5.2
Sr rise of 44 mo1/liter 7 6.0 7 5.3 0.7 to 5.6
Dialysis required 1 0.8 0 — 0.8 to 2.1
High-osmolar Low-osmolar
N=43 % N=74 %
Non-randomized subjects
Scr rise of 25% 10 23.3 8 10.8
Scr rise of 50% 2 4.7 3 4.1
Scr rise of 44 .tmol/1iter 7 16.3 8 10.8
Dialysis required 0 — 2 2.7
Scr is serum creatinine. Note that the 95% confidence intervals for
the differences between the randomized groups are one-tailed.
high-osmolar and —1.5 imol/liter (—0.02 mg/dl) in those ran-
domized to low-osmolar contrast (95% confidence interval [CI]
for the difference —6.1 to 16.1 j.mo1/liter = —0.07 to 0.18
mg/dl). The corresponding figures for the non-randomized
groups were 17 j.mo1/1iter (0.19 mgldl) in the high-osmolar and
4 jmo1/liter (0.04 mg/dl) in the low-osmolar group. Because
serum creatinine is not linearly related to glomerular filtration
rate, we also compared the response to the two types of
contrast after inverse and logarithmic transformation of the
data. This analysis also failed to reveal any statistically signif-
icant difference between the high- and low-osmolar media.
Multivariate analysis of the effect of contrast
Given the lack of statistically significant benefit with low-
osmolar contrast, and the difference in the randomized groups
at baseline which might have contributed to this situation, we
analyzed the randomized subjects by multiple linear regression
analysis. The change in serum creatinine after contrast served
as the dependent. The independent variables used were the type
and route of administration of contrast, presence of diabetes,
and the pre-contrast serum creatinine. The type of contrast did
not significantly predict the change in serum creatinine in these
models.
Risk factors for contrast nephropathy
To identify factors which might predispose to contrast
nephropathy and to examine the effect of low-osmolar contrast
in various risks groups we stratified the randomized subjects
into four groups: those with a pre-contrast serum creatinine
between 120 and 200 mol/liter (1.35 and 2.25 mg/dl) with and
without diabetes, and those with a pre-contrast serum creati-
nine greater than 200 jmol/liter (2.25 mg/dl) with and without
diabetes. The incidence of contrast nephropathy, as defined by
a 25% increment in serum creatinine after high- or low-osmolar
contrast, in each of the strata is shown in Table 5. These results
Table 5. The incidence of a 25% rise in serum creatinine with high-
or low-osmolar contrast in the randomized trial after stratification by
serum creatinine and the presence of diabetes mellitus
High-
Stratum
osmolarN % Low-oN smolar%
Nondiabetic with serum creatinine 3/92 3.3 1/97 1.0
< 200 > 120 smol/liter
Diabetic with serum creatinine 0/8 — 2/17 11.8
<200> 120 tmol/liter
Nondiabetic with serum creatinine 1/13 7.6 1/11 9.!
> 200 mo1/liter
Diabetic with serum creatinine 3/4 75.0 1/7 14.3
> 200
.tmol/1iter
suggest that those with more severe renal impairment, espe-
cially when due to diabetic nephropathy, are at the highest risk
of contrast nephropathy. There is not a consistent trend to a
lower incidence of contrast nephropathy with low-osmolar
contrast across the strata but the lower incidence with low-
osmolar contrast in the group with advanced diabetic nephrop-
athy is interesting given the results of another recent trial [14].
When the data for all subjects, irrespective of randomization
or type of contrast prescribed, was stratified and analyzed in the
same fashion as for the randomized patients the results sug-
gested even more strongly that the degree of renal impairment,
especially in diabetics, is predictive of the risk for contrast
nephropathy. The serum creatinine rose by more than 25% after
contrast in 16 of 266 (6%) with a serum creatinine less than 200
jimol/liter (2.25 mg/dl) without diabetes, in 4 of 36 (11%)
diabetics with a serum creatinine less than 200 mol/liter (2.25
mg/dl), in 8 of 48 (16.7%) of those with a serum creatinine
greater than 200 mol/liter (2.25 mgfdl) without diabetes, and in
5 of 15 (33.3%) diabetics with a serum creatinine greater than
200 mol/liter (2.25 mg/dl).
In a series of multiple linear and logistic regression models
the only variables which were statistically significantly associ-
ated with a rise in serum creatinine after contrast were the
severity of the pre-existing renal impairment and the presence
of diabetes. In these models the type, volume, and route of
administration of contrast did not add to the prediction of
contrast nephropathy.
Discussion
Our randomized study failed to confirm a clinically important
role for low-osmolar contrast in prevention of contrast nephrop-
athy in subjects with renal impairment. This is compatible with
the results of an earlier study which largely examined subjects
with normal renal function [12]. Table 6 summarizes the results
from the randomized trials of Taliercio et a! [14], Harris et al
[15] and the current trial, pooling data from 657 patients. The
entry criteria was similar in the three studies: pre-contrast
serum creatinine levels of >120 to 134 mol/liter (1.35 to 1.5
mg/dI). However, less than 20% of the patients had severe renal
impairment (pre-serum creatinine greater than 200 moL1liter
2.25 mg/dI). The incidence of clinically important acute renal
failure (defined as >50% increase in serum creatinine after
contrast) was not significantly different: 3.4% after high osmolar
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Table 6. Clinically important contrast nephropathy in renal impairment: High osmolar vs. nonionic contrast
High osmolar Nonionic
>50% Rise in Scra Dialysis required >50% Rise in S. Dialysis required
Reference N % N % N % N %
Taljercjo et a! [14]
Harris et a! [151
Barrettetal
Total
6/152 3.9 2/152 1.3
1/50 2.0 0 0
4/117 3.4 1/117 0.9
11/319 3.4 3/319 0.9
3/155 1.9
1/51 2.0
2/132 1.5
5/338 1.5
1/155 1
0 0
0 0
1/338 0.3
a >50% increase in serum creatinine within two days of contrast administration
versus 1.5% after nonionic contrast. The relative risk of devel-
oping clinically important acute renal failure after high osmolar
contrast compared to nonionic contrast was 2.27 (95% CI: 0.82
to 6.65). Therefore, we conclude that the potential benefit of
nonionic contrast in preventing contrast nephropathy in pa-
tients with moderate pre-existing renal impairment is likely to
be small.
However, given that the level of renal impairment, especially
in diabetics, is the best predictor of contrast nephropathy and
given the small number of patients studied with severe pre-
existing renal failure further trials are indicated in patients,
especially diabetics, with serum creatinine greater than 200
mol/liter (2.25 mgldl).
A limitation of our study is that it does not have sufficient
power to exclude a 50% reduction in the incidence of contrast
nephropathy, as assessed by any outcome, with low-osmolar
contrast. Given the results, we would have required a sample
size of over 1300 subjects per group to exclude such a benefit,
using a rise of 25% in serum creatinine to diagnose a case of
contrast nephropathy [181. However, it is not likely that even
such an expanded cohort of patients would alter our conclu-
sions given the very low incidence of clinically important renal
failure observed when the results of three recent studies are
pooled (Table 6). Our study did have a power of greater than 0.8
to detect a true difference of at least 10 rmol/liter (0.11 mg/dl)
in the change in serum creatinine after contrast between high-
and low-osmolar media, and no such difference was found. This
is contrary to the findings of another recent trial 114],
Although the data suggest that low-osmolar media may have
some benefit, we cannot conclude that low-osmolar contrast
prevents contrast nephropathy in subjects with impaired renal
function, If the point estimates of incidence in our randomized
trial (similar to the incidence observed when three recent
studies are pooled) are correct, one would need to treat 53
subjects of the type in our randomized trial with low-osmolar
contrast at a marginal cost of Canadian $4770 to prevent one
case having a 50% rise in serum creatinine after contrast. If
low-osmolar contrast was reserved for those with a pre-contrast
serum creatinine of greater than 200 rmol/liter (2.25 mg/dl) with
or without diabetes one would only need to treat 8 such subjects
at a marginal cost of Canadian $720 to prevent one such event.
It is of interest that the incidence of contrast nephropathy
was low in our subjects who did not receive any prophylactic
treatment. In fact, our results are similar to those of others who
employed a prophylactic fluid loading regimen [121. While
avoidance of dehydration is desirable the benefits of intentional
fluid loading or any other prophylactic measure need to be
established by adequate randomized controlled trials before
routine use can be recommended.
We chose to use serum creatinine to measure outcome, even
though it is an insensitive measure of renal function, as it has
the advantages of being easy to measure and of being able to
detect clinically important changes in renal function. Others
have used enzymuria to compare the nephrotoxicity of high-
and low-osmolar contrast, but the results have not been con-
sistent and were often of dubious clinical relevance [7—111.
We conclude that the incidence of clinically important con-
trast nephropathy is low after both high and low-osmolar
contrast media in subjects with moderate pre-existing renal
impairment. Larger studies will be required to define the precise
role of low-osmolar media for prevention of contrast nephrop-
athy in subjects with more severe impairment of renal function.
Since those with diabetic nephropathy seem to be at greatest
risk [13], it would make most sense to conduct any further trials
in such patients.
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